Mircera
Sponsors
Hoffmann-La Roche, Samsung Medical Center, Genexine, Inc., Biocad, PT Kalbe Genexine Biologics
Conditions
Anaemia Associated With Chronic Kidney DiseaseAnemiaChronic Kidney DiseaseKidney Disease, ChronicPDRenal Anemia of Chronic Kidney DiseaseRenal Insufficiency, Chronic
Phase 2
Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
CompletedNCT02044653
Start: 2014-04-15End: 2017-04-20Updated: 2017-10-16
Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis
CompletedNCT03519243
Start: 2017-10-24End: 2018-12-10Updated: 2021-03-04
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
CompletedNCT03552393
Start: 2018-08-03End: 2021-07-19Updated: 2022-03-07
Phase 3
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
CompletedNCT00442702
Start: 2007-09-30End: 2010-08-31Updated: 2011-12-19
A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient
CompletedNCT04155125
Start: 2020-07-02End: 2023-06-30Updated: 2023-12-22
Phase 4
Unknown Phase
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)
CompletedNCT01417377
Start: 2010-05-31End: 2012-03-31Updated: 2017-07-13
An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice
CompletedNCT02263833
Start: 2009-09-30End: 2012-08-31Updated: 2016-09-07
Observational Study of MIRCERA in Users of Self-Application and Multidose Systems
CompletedNCT02540213
Start: 2009-01-31End: 2010-11-30Updated: 2015-12-22
A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis
CompletedNCT02567188
Start: 2009-04-30End: 2011-04-30Updated: 2025-09-11